Nicox Announces Extension of Cash Runway

Nicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.